Business - Briefly   

Strides Arcolab's pact with U.S. firm

MUMBAI: Strides Arcolab has signed a license agreement with the U.S.-based KV Pharmaceutical Company for exclusive marketing rights in the U.S. and Canada for ten new generic drugs. KV Pharma will also make an investment of $11.3 million through redeemable preference shares of Strides Arcolab, subject to shareholders' approval.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Tamil Nadu | Andhra Pradesh | Karnataka | Kerala | New Delhi | Other States | International | Opinion | Business | Sport | Miscellaneous | Engagements |
Advts: Classifieds | Employment | Obituary | Updates: Breaking News |

Stories in this Section

Bajaj Auto plans to launch 3 scooters
Reva unveils next generation car
`Intelligent' system will track down tax evaders, says Chidambaram
FM launches e-payment of indirect taxes
Sensex recovers early losses
Premier returns to Indian auto market
Jet set to launch service to U.S.
Rupee at new high
Nokia team meets Maran
Exchange rates
Bullion rates
Satyam ADS priced at $21.50
FDI in retail under discussion stage
Strides Arcolab's pact with U.S. firm
HDFC AMC ups stake in TV 18
Sun Micro to acquire Tarantella
Central Bank launches scheme
Productivity award for Suguna
Shasun Chemicals pact with Codexis of U.S.
Software for TV channel operations
Canadian Crystaline launches desalination plant
ColdWatt opens India development centre
Award for Midas Tech
Seven Hills secures Canadian contract
BenQ to set up R&D centre
BPL Mobile to expand in Kerala
Jewellery and wedding mall

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu